Charting a path toward combination therapy for Alzheimer's disease (Q38300738)

1 September 2017

1 reference

title

Charting a path toward combination therapy for Alzheimer's disease (English)

1 reference

1 September 2017

0 references

Reisa Sperling

1 reference

1 September 2017

Robert Temple

1 reference

1 September 2017

Diane Stephenson

1 reference

1 September 2017

Dan Perry

1 reference

1 September 2017

Cynthia Bens

1 reference

1 September 2017

Lisa J Bain

1 reference

1 September 2017

Donald Berry

1 reference

1 September 2017

Michael Krams

1 reference

1 September 2017

David Dilts

1 reference

1 September 2017

Johan Luthman

1 reference

1 September 2017

Debra Hanna

1 reference

1 September 2017

John McKew

1 reference

1 September 2017

F Owen Fields

1 reference

1 September 2017

Stephen Salloway

1 reference

1 September 2017

Russell Katz

1 reference

1 September 2017

publication date

26 December 2014

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

1 September 2017

published in

1 reference

1 September 2017

1 reference

1 September 2017

1 reference

1 September 2017

page(s)

107-113

1 reference

Pathways towards and away from Alzheimer's disease

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

A history of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Alzheimer's disease: clinical trials and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Testing the right target and right drug at the right stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Evidence for ordering of Alzheimer disease biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

Alzheimer's disease public-private partnerships: A landscape of the global nonprofit community

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995168

10.1586/14737175.2015.995168

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference